Purolite, a subsidiary of Ecolab that produces purification resins for drug manufacturing, earmarked at least $190 million to build a production plant that will employ 170 workers.
ST. PAUL, Minn.--(BUSINESS WIRE)--Ecolab Inc., the world’s water, hygiene and infection prevention company, today announced a further expansion of its Purolite business with the addition of a new biologics resin manufacturing facility in Landenberg, Pennsylvania. Construction plans for the new facility are underway and will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Purolite, an Ecolab company and manufacturer of synthetic and agarose-based resins used in the bioprocessing industry, has expanded, and extended its agreement until 2032 with life sciences company Repligen Corporation to supply five ligands.
A ribbon-cutting ceremony was held on Thursday, October 13 to celebrate the expansion of Purolite’s bioprocessing resin production to meet the growing demand for biopharmaceutical products globally.
(Reuters) -Hygiene company Ecolab Inc on Thursday agreed to buy Purolite, whose technology can be used in mRNA vaccine purification, in a $3.7 billion all-cash deal to add weight to its pharmaceutical-focused business.
Purolite Ltd., a leading manufacturer of resin-based separation, purification and extraction technologies, today announces that its Praesto® agarose-based chromatography resin range is being utilised for the commercial manufacturing of FDA-approved biotherapeutics. Praesto resins are an integral technology used by biopharmaceutical developers for the purification of modern medicines targeting the treatment of cancer, rheumatoid arthritis, dementia and diabetes.